Perseus Proteomics Inc.(4882) Summary
4882
TSE Growth
Perseus Proteomics Inc.
Result
ー
145
JPY
+4
(+2.84%)
Sep 4, 3:30 pm JST
0.92
USD
Sep 4, 2:30 am EDT
PER
ー
PBR
2.34
Yield
ー%
Margin Trading Ratio
ー
PTS
outside of trading hours
ー
ー
Stock Price
Sep 4, 2026
Opening
Sep 4, 9:00 am
141
JPY
0.90
USD
Previous Close
Sep 3
141
JPY
0.89
USD
High
Sep 4, 2:41 pm
145
JPY
0.92
USD
Low
Sep 4, 9:00 am
141
JPY
0.90
USD
Volume
129,900
Trading Value
0.02B
JPY
0.12M
USD
VWAP
142.69
JPY
0.91
USD
Minimum Trading Value
14,500
JPY
92
USD
Market Capitalization
2.67B
JPY
0.02B
USD
Number of Trades
50
Opening
ー
ー
JPY
Previous Close
Sep 4
144
JPY
High
ー
ー
JPY
Low
ー
ー
JPY
Volume
ー
Trading Value
ー
JPY
VWAP
ー
JPY
Minimum Trading Value
ー
Market Capitalization
ー
Number of Trades
ー
PTS Stock Price
Liquidity & Number of Trades
As of Sep 4, 2026
Liquidity
Liquidity Grade
| Liquidity | Number Of Trades | Distribution |
|---|---|---|
| High | Over 1,000 | 13.9% |
| Slightly-High | 400 to 1,000 | 18.5% |
| Mid | 50 to 400 | 39.0% |
| Slightly-Low | 10 to 50 | 17.6% |
| Low | Less than 10 | 11.0% |
Slightly High
1-Year Average
440
1-Year High
Mar 9, 2026
13,130
Margin Trading
| Date | Short Interest | Long Margin Positions | Ratio |
|---|---|---|---|
| Aug 28, 2026 | 0 | 1,910,700 | ー |
| Aug 21, 2026 | 0 | 1,912,300 | ー |
| Aug 14, 2026 | 0 | 2,037,000 | ー |
| Aug 7, 2026 | 0 | 2,127,700 | ー |
| Jul 31, 2026 | 0 | 2,149,900 | ー |
Similar Stocks
Company Profile
Perseus Proteomics Inc. is a biotech venture company specializing in the development of high-performance antibody drugs and research reagents targeting cancer.
Sector
Pharmaceuticals
Website
Perseus Proteomics Inc. is a biotech venture company that leverages its academic drug discovery network originating from the University of Tokyo to conduct research and development of antibody drugs. Utilizing proprietary antibody acquisition and engineering technologies, the company is advancing the development of therapeutic antibodies targeting cancer and hematological diseases. Its main pipeline includes PPMX-T002, a radioisotope-labeled antibody targeting cadherin 3, and PPMX-T003, an antibody targeting transferrin receptor 1. The company's revenue is derived from upfront payments from out-licensing drug candidates to domestic and international pharmaceutical companies, milestone payments based on development progress, and royalty income as a percentage of sales after market launch.